NOVOLOG MIX 50/50
LOE ApproachingBLASUBCUTANEOUSINJECTABLE
Approved
Aug 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOVOLOG MIX 50/50 is a biphasic insulin injection combining 50% insulin aspart (rapid-acting) and 50% insulin aspart protamine (intermediate-acting). It is used to treat both type 1 and type 2 diabetes mellitus. The dual-component formulation provides both mealtime and basal glucose control in a single injection.
LOE Approaching
As LOE approaches, the brand team will shift focus from growth expansion to lifecycle management and defending market share against generic and biosimilar entrants.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NOVOLOG MIX 50/50 currently shows zero linked job openings, reflecting its transition into LOE phase. Working on this product offers experience in mature brand management, payer negotiation, and competitive defense—valuable skills for career progression, but with limited growth upside.
Brand ManagerMarket Access Manager
Worked on NOVOLOG MIX 50/50 at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.